Rosch 2019 JCR CoverLetter - Royal Society of Chemistry · 2019. 7. 9. · S-1 Supplemental...
4
S-1 Supplemental Information Enhancing Chemoradiation of Colorectal Cancer Through Targeted Delivery of Raltitrexed by Hyaluronic Acid Coated Nanoparticles Justin G. Rosch a , Madeleine R. Landry a , Charles R. Thomas, Jr. b , and Conroy Sun a,b,* a Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA b Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA *Corresponding Author: Conroy Sun, Ph.D. Department of Pharmaceutical Sciences Oregon State University 2730 SW Moody Ave Portland, OR 97201-5041, USA Email: [email protected] Phone: 503-346-4699 Electronic Supplementary Material (ESI) for Nanoscale. This journal is © The Royal Society of Chemistry 2019
Transcript of Rosch 2019 JCR CoverLetter - Royal Society of Chemistry · 2019. 7. 9. · S-1 Supplemental...
S-1
Supplemental Information
Enhancing Chemoradiation of Colorectal Cancer Through Targeted
Delivery of Raltitrexed by Hyaluronic Acid Coated Nanoparticles
Justin G. Roscha, Madeleine R. Landrya, Charles R. Thomas, Jr.b, and Conroy Suna,b,*
a Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR
97201, USA
b Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland,
OR 97239, USA
*Corresponding Author:
Conroy Sun, Ph.D.
Department of Pharmaceutical Sciences
Oregon State University
2730 SW Moody Ave
Portland, OR 97201-5041, USA
Email: [email protected]
Phone: 503-346-4699
Electronic Supplementary Material (ESI) for Nanoscale.This journal is © The Royal Society of Chemistry 2019
S-2
Figure S1. TEM of bare CML nanoparticles prior to layer-by-layer deposition.
Figure S2. Fluorescence microscopy images of no treatment and CML-PLA-HA treated wells
after 24 h exposure. The no treatment well is the same as presented in Figure 3. The hyaluronic
acid only nanoparticles showed similar fluorescence to the HARPs.
NT HA
S-3
Figure S3. 24, 48, and 72 h viability curves for raltitrexed and HARPs.
1 10 100 10000
50
100
Raltitrexed 24 h
[Drug], nM
% C
ell V
iabi
lity
1 10 100 10000
50
100
Raltitrexed 48 h
[Drug], nM%
Cel
l Via
bilit
y
1 10 100 10000
50
100
Raltitrexed 72 h
[Drug], nM
% C
ell V
iabi
lity
0.01 0.1 1 10 1000
50
100
Ral NP 24 h
[CM L], µg/ mL
% C
ell V
iabi
lity
0.01 0.1 1 10 1000
50
100
Ral NP 48 h
[CM L], µg/ mL
% C
ell V
iabi
lity
0.01 0.1 1 10 1000
50
100
Ral NP 72 h
[CM L], µg/ mL
% C
ell V
iabi
lity
S-4
Figure S4. Stacked histograms showing the changing fluorescent signal with different treatments
(γH2AX assay).
NT
IR
HARPs
HARPs + IR
